VIDEO: Study shows optogenetic therapy safe, improves visual function in Stargardt disease
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Sam Barone, MD, of Nanoscope Therapeutics discusses efficacy and safety data for the company’s MCO-010 optogenetic therapy.
Barone summarized the findings of two clinical trials for MCO-010: The RESTORE trial, which is investigating the therapy for use as a retinitis pigmentosa treatment, and the STARLIGHT study, which is investigating MCO-010 for Stargardt disease.
“In situations when there is significant degeneration of photoreceptors but there are still intact inner retinal cells, optogenetics therapy allows for the opportunity to transduce those cells of the inner retina to express a light sensitive protein, turning them into de facto photoreceptors,” he said.
Collapse
Barone S. Nanoscope Therapeutics. Presented at: Eyecelerator@AAO; Nov. 2, 2023; San Francisco.
Read more about
Click Here to Manage Email Alerts